Publication | Open Access
CD133+ Tumor Initiating Cells in a Syngenic Murine Model of Pancreatic Cancer Respond to Minnelide
74
Citations
37
References
2014
Year
As Minnelide is currently under phase I clinical trial, its evaluation in reducing tumor burden by decreasing TIC as well as non-TIC population suggests its potential as an effective therapy.
| Year | Citations | |
|---|---|---|
Page 1
Page 1